Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
By Joanna M. Wardlaw, Eric E. Smith, Geert Jan Biessels, C. Cordonnier, F. Fazekas, R. Frayne, R. Lindley, John T. O'Brien, Frederik Barkhof, O. Benavente and 26 more. Lancet Neurology, 2013
4,937 citations recorded by the source corpus.
Summary Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and brain atrophy. SVD can present as a stroke or cognitive decline, or can have few or no symptoms. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive deficits, physical disabilities, and other symptoms of neurodegeneration. Terminology and definitions for imaging the features of SVD vary widely, which is also true for protocols for image acquisition and image analysis. This lack of consistency hampers progress in identifying the contribution of SVD to the pathophysiology and clinical features of common neurodegenerative diseases. We are an international working group from the Centres of Excellence in Neurodegeneration. We completed a structured process to develop definitions and imaging standards for markers and consequences of SVD. We aimed to achieve the following: first, to provide a common advisory about terms and definitions for features visible on MRI; second, to suggest minimum standards for image acquisition and analysis; third, to agree on standards for scientific reporting of changes related to SVD on neuroimaging; and fourth, to review emerging imaging methods for detection and quantification of preclinical manifestations of SVD. Our findings and recommendations apply to research studies, and can be used in the clinical setting to standardise image interpretation, acquisition, and reporting. This Position Paper summarises the main outcomes of this international effort to provide the STandards for ReportIng Vascular changes on nEuroimaging (STRIVE).
Subfields: Epidemiology, Neurology
View Paper: https://www.semanticscholar.org/paper/f276505d65ea8348b58c300a0f8996abedf0f3ff
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- C. Iadecola
- K. Jellinger
- J. Attems
- Joanna M. Wardlaw
- Perminder S. Sachdev
- Geert Jan Biessels
- Berislav Zlokovic
In Neurology
- C. Iadecola
- Berislav Zlokovic
- Melanie D. Sweeney
- J. Attems
- A. Sagare
- Axel Montagne
- K. Jellinger
- Maiken Nedergaard
Citations in the corpus
- Post-stroke dementia – a comprehensive review (2017, methodology): “Neuroimaging standards with a generally accepted terminology allowing comparison of findings between different centers have been suggested (STandards for ReportIng Vascular changes on nEuroimaging, STRIVE) [69].”
- Rationale, design and methodology of the image analysis protocol for studies of patients with cerebral small vessel disease and mild stroke (2015, methodology): “Lacunar infarcts (Wardlaw et al. 2013a) coexist with white matter hyperintensities (WMH) (Pantoni 2002; Roman et al. 2002) enlarged perivascular spaces, lacunes, and microhemorrhages that occur silently ª 2015 The Authors.”
- Vascular Contributions to Cognitive Impairment and Dementia Including Alzheimer’s Disease (2014, background): “hyperintense rim defined as lacune of presumed vascular origin) [76] Mostly undetectable.”
- Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities; Results of the WMH Segmentation Challenge (2019, background): “for ReportIng Vascular changes on nEuroimaging (STRIVE) criteria [3].”
- Vascular dysfunction – the disregarded partner of Alzheimer’s disease (2019, positive): “…defined above, further inclusion of SVD features in the differential biological approach in sporadic AD, ADAD [65] and other dementias would be relatively easy to achieve and is highly relevant since SVD of the brain contributes to > 50% of all dementias worldwide including AD [19,66–69].”
- Vascular Cognitive Impairment and Dementia (2019, methodology): “Proposed markers include quantitative and semi-quantitative measures of WMH on brain MRI (95,131), composite scores for the burden of vascular brain lesions (132), and metrics derived from diffusion tensor imaging (103).”
- Impact of multiple pathologies on the threshold for clinically overt dementia (2017, background): “The advent of advanced imaging techniques such as MRI, however, has led to identification of various, asymptomatic processes [78, 134], the clinical significance of which are widely debated [106].”
- Evaluation of a deep learning approach for the segmentation of brain tissues and white matter hyperintensities of presumed vascular origin in MRI (2017, neutral): “…is widely being performed in MR images of older patients and is especially relevant in the context of neurovascular and neurodegenerative diseases (De Groot et al., 2000; Ikram et al., 2008; De Bresser et al., 2010a,b, Driscoll et al., 2009; Giorgio and De Stefano, 2013; Wardlaw et al., 2013).”
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup (2024, neutral): “State-of-the-art meth-ods in neuroimaging of small-vessel disease 203 are reviewed in the recent STRIVE-2 guidelines.”
- The overlap between vascular disease and Alzheimer’s disease - lessons from pathology (2014, background): “SVD is a frequent cause of white matter lesions (WMLs; leukoaraiosis) that are increasingly detected by neuroimaging [118-121].”